• In 2016, we discovered that our lead molecule, ONC201, targets a GPCR known as dopamine receptor D2 (DRD2) and that our other molecules in development also target different GPCRs.   Although GPCRs are the most common target in modern medicine (30-50% of all drugs), GPCRs have not historically been targeted in oncology.  Recently, there has been an increased interest in the research community about targeting GPCRs in oncology, creating an opportunity for Oncoceutics and our GPCR-targeting molecules.

    The article “GPCRs, Desirable Therapeutic Targets in Oncology,” written by Oncoceutics and published on January 24th, 2017, provides background information on GPCRs as drug targets in general, summarizes why GPCRs are desirable therapeutic targets specifically for oncology, describes the challenges of drug discovery for GPCRs, and provides recent examples of efforts to target GPCRs in oncology.